Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced positive interim safety results from Cohort 1 of their first human trial for BioLexa, aimed at treating atopic dermatitis. A total of ten subjects received the treatment twice daily for 14 days, with no serious adverse events reported. CEO Robb Knie highlighted this milestone as the company prepares for Cohort 2 enrollment later in the year. BioLexa is designed to combat bacterial biofilms that complicate infections, offering a novel mechanism for treating conditions associated with these biofilms.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a Sponsored Research Agreement with Washington University to advance the development of HT-ALZ, aimed at treating symptoms associated with Alzheimer's disease. The research will be led by Dr. John Cirrito and Dr. Carla Yuede, focusing on amyloid-beta metabolism's role in Alzheimer's. Hoth's CEO emphasized the goal of developing innovative therapeutics to meet patient needs and enhance shareholder value.

Hoth Therapeutics (NASDAQ: HOTH) announced positive preclinical trial results for its investigational therapy HT-KIT, aimed at treating mast cell-derived cancers and anaphylaxis. Conducted in humanized mast cell neoplasm models, the study demonstrated that HT-KIT significantly reduces KIT expression, induces apoptosis in neoplastic human mast cells, and inhibits tumor growth. These findings indicate HT-KIT's potential as a targeted treatment for patients affected by various aggressive cancers associated with the KIT pathway. The results were shared on June 3, 2021, during a shareholder presentation.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a virtual information session on its pipeline product, HT-KIT, aimed at treating mast cell-derived cancers and anaphylaxis, set for June 3, 2021. Dr. Glenn Cruse will present positive preclinical results, indicating HT-KIT's efficacy in inducing apoptosis in neoplastic mast cells, leading to significant tumor reduction without noticeable toxicity in animal models. Hoth aims to address unmet medical needs, focusing on patient welfare and shareholder value.

On May 24, 2021, Hoth Therapeutics announced its participation as an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting, running from May 24th through July 6, 2021. The company focuses on developing treatments for rare cancers and discusses its HT-KIT and HT-001 therapeutics. HT-KIT targets cancers from aberrant KIT signaling, while HT-001 addresses skin toxicities from EGFR inhibitor therapy. CEO Robb Knie expressed excitement about contributing to oncology advancements.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) will host a virtual information session on May 18, 2021, at 11:00 AM ET, focusing on its pipeline product, HT-005 Z-Pods™, a novel endocannabinoid treatment for Cutaneous Lupus Erythematosus (CLE). Dr. Adam Friedman will discuss the treatment's potential, efficacy data from an animal study, and the unmet medical needs it addresses. The session aims to engage shareholders and interested parties. CEO Robb Knie emphasized the company's commitment to innovating therapies for patient needs and driving shareholder value.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an expansion of its research agreement with Virginia Commonwealth University focused on developing the COVID-19 therapeutic HT-002. This decision comes after promising preclinical results from Dr. Michael Peters using live virus assays. The research will explore HT-002's effectiveness against SARS-CoV-2 variants, informed by recent molecular modeling studies. Hoth holds an exclusive license for this peptide therapeutic, which aims to provide new treatments for COVID-19.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced plans to develop its HT-KIT mRNA Frame Shifting Therapeutic targeting rare diseases affecting fewer than 200,000 people in the U.S., including various rare cancers such as aggressive systemic mastocytosis and acute myeloid leukemia. The company aims to secure Orphan Drug Designation (ODD) for HT-KIT, which offers extended market exclusivity and financial benefits during development. This strategic move aligns with Hoth's focus on improving treatment options for patients with unmet medical needs.

Hoth Therapeutics (NASDAQ: HOTH) has announced the initiation of its first human clinical trial for topical BioLexa, targeting mild to moderate atopic dermatitis (eczema). This milestone addresses a significant unmet need for enhanced therapeutic solutions for eczema patients. The clinical trial is being conducted in Australia, with updates available on Hoth's website and ClinicalTrials.gov. CEO Robb Knie expressed enthusiasm for this advancement, highlighting its potential to improve patient quality of life.